How long does it take for platelets to start to drop after stopping taking Eltrombopag (Revlan)?

Eltrombopag is an oral thrombopoietin receptor agonist (TPO-RA), which activates TPO on the surface of megakaryocytes. Receptor (c-Mpl), promotes megakaryocyte proliferation and platelet production, and is widely used to treat chronic immune thrombocytopenia (ITP) and liver disease-related thrombocytopenia. The drug has good efficacy and controllability, but its effect depends on continuous receptor stimulation. Once the drug is stopped, the signal that promotes platelet production in the body will gradually weaken, resulting in a drop in platelet levels.

Generally speaking, patients' platelets begin to decrease approximately 7 to 14 days after stopping eltrombopag. In some individuals, a downward trend can even be observed 3 to 5 days after stopping the drug. This is because the half-life of eltrombopag in the body is relatively short (about 26 to 35 hours). When the drug concentration gradually decreases, the proliferation of megakaryocytes and the release of platelets slow down. If the patient's original immune platelet destruction continues and the stimulation of the hematopoietic system is interrupted, the platelet count will usually return to the pre-treatment level within 2 weeks, or even decline significantly.

In clinical practice, the rate of platelet decline after discontinuation of medication is closely related to the severity of the patient's condition, basic bone marrow function, and duration of medication. For patients with chronic diseases such as ITP, if the platelet count has been maintained for a long time and the condition is stable before stopping the drug, the rate of decline may be slower; conversely, if the patient is highly dependent on the drug or has experienced a rapid rebound phenomenon, the platelet count may drop sharply in a short period of time after the drug is stopped. In order to avoid the risk of serious bleeding, doctors usually recommend gradually reducing the dose and discontinuing the medication, and monitoring platelet levels every 3 to 5 days after stopping the medication. If necessary, low-dose medication can be temporarily resumed to smooth the transition.

In general, the platelet-raising effect of eltrombopag is reversible and controllable, but the decrease after drug withdrawal is an expected physiological response. Patients should avoid stopping the drug on their own or suddenly interrupting treatment, especially those with a history of bleeding or extremely low baseline platelet values. Gradually reducing the dose under the guidance of a doctor and dynamically adjusting the plan according to platelet changes are the keys to ensuring safety and maintaining efficacy. If obvious ecchymosis, gum bleeding or other bleeding symptoms occur after stopping the drug, you should seek medical attention immediately to prevent complications caused by a sudden drop in platelets.

Reference materials:https://www.drugs.com/